Search

Your search keyword '"Chikuma, Masahiko"' showing total 175 results
Start Over Author "Chikuma, Masahiko"
175 results on '"Chikuma, Masahiko"'

6. A novel isomerization on interaction of antitumor-active azole-bridged dinuclear platinum(II) complexes with 9-ethylguanine. Platinum(II) atom migration from N2 to N3 on 1,2,3-triazole

Author

Komeda, Seiji, Lutz, Martin, Spek, Anthony L., Yamanaka, Yasuyuki, Sato, Takaji, Chikuma, Masahiko, and Reedijk, Jan

Subjects
Chemical research -- Analysis, Isomerization -- Physiological aspects, Platinum -- Physiological aspects, Coordination compounds -- Physiological aspects, Guanine -- Physiological aspects, Ethylene -- Physiological aspects, Solution (Chemistry) -- Physiological aspects, Chemistry
Abstract

Research has been conducted on the dinuclear platinum(II) complexes. The reactions of these complexes with 9-ethylguanine have been monitored in aqueous solution via (super)1 NMR spectroscopy and the results are described.

Published
2002

8. New antitumor-active azole-bridged dinuclear platinum(II) complexes: synthesis, characterization, crystal structures, and cytotoxic studies

Author

Komeda, Seiji, Lutz, Martin, Spek, Anthony L., Chikuma, Masahiko, and Reedijk, Jan

Subjects
Platinum compounds -- Structure, Platinum compounds -- Atomic properties, Chemistry, Inorganic -- Research, Molecular structure -- Research, Chemistry
Abstract

The synthesis, characterization and three single-crystal X-ray structures, as well as the cytotoxic study of the three new azole-bridged dinuclear platinum(II) complexes are reported. A cytotoxicity assay of these dinuclear platinum(II) compounds on human tumor cell lines was performed and the implications of each complex is discussed in the context of a structure-activity relationship.

Published
2000

9. Interaction of platinum agents, cisplatin, carboplatin and oxaliplatin against albuminin vivorats andin vitrostudy using inductively coupled plasma-mass spectrometory

Author

Kato, Ryuji, primary, Sato, Takaji, additional, Iwamoto, Asuka, additional, Yamazaki, Taku, additional, Nakashiro, Satomi, additional, Yoshikai, Shoichi, additional, Fujimoto, Ayumi, additional, Imano, Hideki, additional, Ijiri, Yoshio, additional, Mino, Yoshiki, additional, Chikuma, Masahiko, additional, Tanaka, Kazuhiko, additional, and Hayashi, Tetsuya, additional

Published
2019
Full Text
View/download PDF

10. Does Carboplatin Change to Cisplatin?

Author

Fujimoto, Ayumi, primary, Kato, Ryuji, additional, Sato, Takaji, additional, Okada, Ryuji, additional, Yoshikai, Shoichi, additional, Endo, Mikiko, additional, Takahashi, Kodai, additional, Imano, Hideki, additional, Ijiri, Yoshio, additional, Mino, Yoshiki, additional, Chikuma, Masahiko, additional, Tanaka, Kazuhiko, additional, and Hayashi, Tetsuya, additional

Published
2018
Full Text
View/download PDF

12. A Novel Analytical Method of Cisplatin Using the HPLC with a Naphthylethyl Group Bonded with Silica Gel (πNAP) Column

Author

Kato, Ryuji, primary, Sato, Takaji, additional, Kanamori, Michiko, additional, Miyake, Mizuho, additional, Fujimoto, Ayumi, additional, Ogawa, Kyohei, additional, Kobata, Daiki, additional, Fujikawa, Tomoya, additional, Wada, Yukari, additional, Mitsuishi, Rintaro, additional, Takahashi, Kodai, additional, Imano, Hideki, additional, Ijiri, Yoshio, additional, Mino, Yoshiki, additional, Chikuma, Masahiko, additional, Tanaka, Kazuhiko, additional, and Hayashi, Tetsuya, additional

Published
2017
Full Text
View/download PDF

13. Interaction of platinum agents, cisplatin, carboplatin and oxaliplatin against albumin in vivo rats and in vitro study using inductively coupled plasma‐mass spectrometory.

Author

Kato, Ryuji, Sato, Takaji, Iwamoto, Asuka, Yamazaki, Taku, Nakashiro, Satomi, Yoshikai, Shoichi, Fujimoto, Ayumi, Imano, Hideki, Ijiri, Yoshio, Mino, Yoshiki, Chikuma, Masahiko, Tanaka, Kazuhiko, and Hayashi, Tetsuya

Subjects
ALBUMINS, INDUCTIVELY coupled plasma mass spectrometry, CISPLATIN, OXALIPLATIN, DRUG monitoring, GENERIC drugs
Abstract

The protein binding rates (PBR) of platinum‐containing agents cisplatin (CDDP), carboplatin (CBDCA) and oxaliplatin (L‐OHP) have been reported as 98%, 25–50% and 98%, respectively. To investigate the protein‐binding properties of albumin with cisplatin, carboplatin and oxaliplatin, inductively coupled plasma mass spectrometry (ICP‐MS) was used to measure their plasma concentration in rats over time. The study also examined the effects of cisplatin, carboplatin and oxaliplatin‐binding on albumin in vitro, using CD spectrometry and native‐polyacrylamide gel electrophoresis (native PAGE). The ratios of PBR to irreversible PBR, of cisplatin and oxaliplatin were 98%:98% and 90%:87%, respectively, indicating a higher affinity for irreversible binding with albumin. That of carboplatin was 25%:10%, indicating 60–70% reversible binding with albumin. The plasma protein binding rate concentrations of cisplatin, carboplatin and oxaliplatin after in vivo administration were 96%, 15% and 80%, respectively. The CD spectrometry of albumin was unaffected by cisplatin, carboplatin and oxaliplatin binding. Though similar protein binding rates were observed with oxaliplatin and cisplatin, oxaliplatin had a higher mobility rate during PAGE. It was confirmed that the binding of cisplatin and oxaliplatin with albumin affected its electric charge but not the structure. In conclusion, cisplatin and oxaliplatin bind irreversibly with albumin in plasma and may irreversibly interact with tissue protein and/or DNA. The difficulties involved with predicting the tissue concentrations of cisplatin and oxaliplatin from their plasma concentration inhibits their therapeutic drug monitoring. On the contrary, carboplatin, like some generic drugs, reversibly binds to plasma proteins. It is, therefore, possible to conduct therapeutic drug monitoring for carboplatin. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results